肿瘤细胞治疗研究
英文原题：Systemic Therapy for Advanced Pancreatic Cancer in 2025: Current Standard-of-Care and Emerging Therapeutic Strategies.
Systemic Therapy for Advanced Pancreatic Cancer in 2025: Current Standard-of-Care and Emerging Therapeutic Strategies.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
晚期胰腺癌仍是发达国家癌症死亡的主要原因之一，过去十年间其全身治疗进展有限。本综述重点介绍近期一线标准治疗选择，并探讨生物标志物驱动的策略，尤其是同源重组缺陷用于个体化治疗选择。我们强调肿瘤下一代测序的应用如何塑造精准治疗，包括肿瘤不可知靶点，如 KRAS 野生型肿瘤中的 NRG1 融合和 BRAF 改变。KRAS 抑制剂、PROTACs、肿瘤电场治疗以及针对 MTAP 缺失肿瘤的 PRMT5 抑制剂的进展正在迅速扩展患者的潜在治疗选择。靶向 Claudin18.2 和 CXCR4 的新兴免疫疗法为克服肿瘤耐药带来了希望。总之，这些策略凸显了分子分层、合成致死和新型靶点在改善胰腺癌生存方面的前景。
Advanced pancreatic cancer remains a leading cause of cancer death in developed countries and has seen limited progress in systemic therapy over the past decade. This review highlights recent first-line standard of care treatment options and explores biomarker-driven strategies, particularly homologous recombination deficiency for personalized treatment selection.
We emphasize how the adoption of tumor next-generation sequencing is shaping precision therapy, including tumor-agnostic targets such as NRG1 fusions and BRAF alterations in KRAS wild-type tumors. Advances in KRAS inhibitors, PROTACs, tumor treating fields, and PRMT5 inhibitors for MTAP-deleted tumors are rapidly expanding potential treatment options for patients. Emerging immunotherapies targeting Claudin18. 2 and CXCR4 offer hope to overcome tumor resistance.
Together, these strategies underscore the promise of molecular stratification, synthetic lethality, and novel targets to improve pancreatic cancer survival.
MEMBER ACCOUNT
登录成功会直接打开下一页。
